“Cannabidiol (CBD) is currently being investigated as a novel therapeutic for the treatment of CNS disorders like schizophrenia and epilepsy.
These results suggest that CBD is not a substrate of P-gp or Bcrp and may be free from the complication of reduced brain uptake by these transporters.
Such findings provide favorable evidence for the therapeutic development of CBD in the treatment of various CNS disorders.”